Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial-Reference-Cited by-同舟云学术

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial

Published:2011-01 Issue:1 Volume:22 Page:39-48
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Poveda A.,Vergote I.,Tjulandin S.,Kong B.,Roy M.,Chan S.,Filipczyk-Cisarz E.,Hagberg H.,Kaye S.B.,Colombo N.,Lebedinsky C.,Parekh T.,Gómez J.,Park Y.C.,Alfaro V.,Monk B.J.

Funder

Johnson & Johnson Pharmaceutical Research & Development

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/22/1/39/19446088/mdq352.pdf

Reference29 articles.

1. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails;Sessa;J Clin Oncol,2005

2. A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens;Krasner;Br J Cancer,2007

3. Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer;Del Campo;Ann Oncol,2009

4. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells;Takahashi;Clin Cancer Res,2001

5. Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies;Meco;Cancer Chemother Pharmacol,2003

Cited by 141 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular biology as a driver in therapeutic choices for ovarian cancer;International Journal of Gynecologic Cancer;2024-08-28

2. Preclinical studies of RA475, a guanidine-substituted spirocyclic candidate RPN13/ADRM1 inhibitor for treatment of ovarian cancer;PLOS ONE;2024-07-11

3. Focus on Trabectedin in Ovarian Cancer: What Do We Still Need to Know?;Drug Design, Development and Therapy;2024-06

4. MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)–Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors—A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study;Cancers;2023-12-20

5. Drug-induced inhibition of HMGA and EZH2 activity as a possible therapy for anaplastic thyroid carcinoma;Cell Cycle;2023-12-17